ArticleMolecules (Basel, Switzerland)2021
Proteomic Signature of Extracellular Vesicles for Lung Cancer Recognition.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- New proteomic signature in circulating extracellular vesicles from tumor-draining and peripheral veins of patients with lung adenocarcinoma.Cancer cell international · 2026Article
- Distinct Proteomic and Glycosylation Signatures Differentiate A549 Tumor and BEAS-2B Nontumor Cell Line-Derived Small Extracellular Vesicles.Molecular & cellular proteomics : MCP · 2026Article
- The Role of Extracellular Vesicles in Transient Ischaemic Attacks and Ischaemic Stroke: A Systematic Review.Journal of extracellular biology · 2026Review
- Exosomal nanocarriers for targeted drug delivery in cancer therapy.Discover oncology · 2026Review
- Identification of Bone Marrow and Peripheral Blood Plasma Extracellular Vesicle Protein Biomarker Signatures for Multiple Myeloma Diagnosis and Staging.International journal of nanomedicine · 2026Article
- Extracellular vesicles as modulators of cancer metabolism and microenvironment.Extracellular vesicles and circulating nucleic acids · 2026Review
- Prospective proteomics for discovering biomarkers in lung adenocarcinoma: a literature review.Translational cancer research · 2025Review
- Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer.Future oncology (London, England) · 2025Review
- Whispers in the Lungs: Small Extracellular Vesicles in Lung Cancer and COPD Crosstalk.Cancers · 2025Review
- Utilizing Nanomaterials in Microfluidic Devices for Disease Detection and Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Secretome and Proteome of Extracellular Vesicles Provide Protein Markers of Lung and Colorectal Cancer.International journal of molecular sciences · 2025Article
- Wildfire-relevant woodsmoke and extracellular vesicles (EVs): Alterations in EV proteomic signatures involved in extracellular matrix degradation and tissue injury in airway organotypic models.Environmental research · 2025Article
- TLN1: an oncogene associated with tumorigenesis and progression.Discover oncology · 2024Review
- Exploring the diagnostic and immune infiltration roles of disulfidptosis related genes in pulmonary hypertension.Respiratory research · 2024Article
- Immune capture and protein profiling of small extracellular vesicles from human plasma.Proteomics · 2024Review
- Article
- Protein profile of purified plasma- and aqueous humor-derived extracellular vesicles from patients with ocular toxoplasmosis.Arquivos brasileiros de oftalmologia · 2024Article
- Extracellular vesicles in neuroblastoma: role in progression, resistance to therapy and diagnostics.Frontiers in immunology · 2024Review
- Air Pollution and Lung Cancer: Contributions of Extracellular Vesicles as Pathogenic Mechanisms and Clinical Utility.Current environmental health reports · 2023Review
- Plasma exosomal protein PLG and SERPINA1 in colorectal cancer diagnosis and coagulation abnormalities.Journal of cancer research and clinical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The proteins of extracellular vesicles (EVs) that originate from tumors reflect the producer cells' proteomes and can be detected in biological fluids. Thus, EVs provide proteomic signatures that are of great interest for screening and predictive cancer diagnostics. By applying targeted mass spectrometry with stable isotope-labeled peptide standards, we assessed the levels of 28 EV-associated proteins, including the conventional exosome markers CD9, CD63, CD81, CD82, and HSPA8, in vesicles derived from the lung cancer cell lines NCI-H23 and A549. Furthermore, we evaluated the detectability of these proteins and their abundance in plasma samples from 34 lung cancer patients and 23 healthy volunteers. The abundance of TLN1, TUBA4A, HSPA8, ITGB3, TSG101, and PACSIN2 in the plasma of lung cancer patients was measured using targeted mass spectrometry and compared to that in plasma from healthy volunteers. The most diagnostically potent markers were TLN1 (AUC, 0.95), TUBA4A (AUC, 0.91), and HSPA8 (AUC, 0.88). The obtained EV proteomic signature allowed us to distinguish between the lung adenocarcinoma and squamous cell carcinoma histological types. The proteomic cargo of the extracellular vesicles represents a promising source of potential biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.